Drug Trial Radar · NCT07737795
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- University of OklahomaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).
Conditions
- Endometrial Cancer
Interventions
OK-1 & PaclitaxelDrug
OK-1 capsules will be administered orally at 3.5-4.5 mg/kg twice a day during a 21-day cycle (3 weeks on, one week off in a 28-day cycle) Other Names: • NSC 726189 Paclitaxel will be administered 60-70 mg/m2 IV on Day 1,8 and 15 (3 weeks on, one week off in a 28-day cycle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Proportion of Patients Who Safely Tolerate The Combination of OK-1 and PaclitaxelTime frame: 12 Months
- Proportion of Patients Who Successfully Completed The Safety Lead-In Phase and Tolerated OK-1 In Combination With Paclitaxel.Time frame: 1 Year
- Proportion of Participants Overrall Response Rate To OK-1 In Comination With PaclitaxelTime frame: 2 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.